<p>马萨诸塞州沃尔瑟姆，2025 年 12 月 23 日（GLOBE NEWSWIRE）——Dyne Therapeutics, Inc.（纳斯达克：DYN）是一家专注于为患有基因驱动的神经肌肉疾病的人群提供功能改善的临床阶段公司，今天宣布任命 Vikram Karnani 为其董事会成员。Karnani 先生在罕见疾病和生物制药领域拥有丰富的商业和高管领导经验，目前担任 Collegium Pharmaceutical 的首席执行官，并在 Horizon Therapeutics 担任多个业务线和职能的领导近十年。</p>
<p>“我们很高兴欢迎 Vikram 加入我们的董事会，随着我们向商业化迈进，” Dyne 董事会主席、Atlas Venture 合伙人 Jason Rhodes 表示。“作为一家快速成功发展的生物技术公司的首席执行官和前商业领导者，Vikram 带来了在产品推出、推动增长和实现价值方面的宝贵经验。他的见解将进一步推动 Dyne 在创造收入和扩展我们的产品组合方面的进展。”</p>
<p>“在我的职业生涯中，我一直专注于将创新转化为高度成功的企业，以释放价值并改善患者的生活，” Vikram Karnani 表示。“Dyne 经过临床验证的药物递送方法和向商业化的进展凸显了其为患有神经肌肉疾病的人群提供有意义的功能改善的潜力。我很高兴在公司努力实现其全部潜力并为股东创造价值的关键阶段加入董事会。”</p>
<p>“Vikram 在运营世界级商业和医疗组织方面的成功记录将为我们的董事会增添重要视角，因为我们为 2027 年第一季度的首次潜在推出做准备，” Dyne 总裁兼首席执行官 John Cox 表示。“他在领导罕见疾病产品组合方面的经验，特别是在快速增长时期，与我们建立一个拥有多个创造价值机会并可能改变神经肌肉疾病护理的商业公司的目标非常契合。”</p>
<p>Karnani 先生自 2024 年 11 月以来担任 Collegium Pharmaceutical 的总裁兼首席执行官。Collegium 是一家多元化的生物制药公司，致力于改善患有严重医疗状况的人的生活，拥有在负责任的疼痛管理领域的领先产品组合以及不断增长的神经精神病学业务。在加入 Collegium 之前，他曾担任安进（Amgen）的执行副总裁和全球商业运营及医疗事务（罕见疾病）总裁，领导公司在以 280 亿美元收购 Horizon Therapeutics 后，整合和发展约 40 亿美元的罕见疾病业务。在 Horizon 的近十年间，Karnani 先生担任多个高级执行职务，包括全球商业运营总裁和首席商业官，帮助公司通过严谨的战略、并购、资本部署和商业化，将其从一家年收入 5 亿美元的企业转变为年收入超过 30 亿美元的罕见疾病领导者。在职业生涯早期，Karnani 先生曾担任治疗和细胞治疗业务的副总裁，并在 Fresenius Kabi 担任战略和业务发展方面的领导职务。</p>
<p>Karnani 先生拥有孟买大学的电气工程学士学位、凯斯西储大学的电气工程硕士学位以及西北大学凯洛格管理学院的 MBA 学位。</p>
<p><strong>关于 Dyne Therapeutics</strong></p>
<p>Dyne Therapeutics 专注于为患有基因驱动的神经肌肉疾病的人群提供功能改善。我们正在开发针对肌肉和中枢神经系统（CNS）的治疗方法，以解决疾病的根本原因。公司正在推进针对肌强直性肌营养不良症 1 型（DM1）和杜氏肌营养不良症（DMD）的临床项目，以及针对面肩肱肌营养不良症（FSHD）和庞贝病的前临床项目。在 Dyne，我们的使命是为个人、家庭和社区提供功能改善。了解更多信息 https://www.dyne-tx.com/，并在 X、LinkedIn 和 Facebook 上关注我们。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含涉及重大风险和不确定性的前瞻性声明。除历史事实陈述外，本新闻稿中包含的所有陈述，包括关于 Dyne 的战略、未来运营、前景和计划、管理目标、FORCETM 平台的潜力、与全球监管机构的互动和提交的时间及结果的预期，以及 zeleciment rostudirsen（z-rostudirsen，也称为 DYNE-251）监管批准和上市的预期时间表，均构成 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。术语 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“可能”、“目标”、“正在进行”、“计划”、“预测”、“项目”、“潜力”、“应该”、“将” 或 “会”，或这些术语的否定形式，或其他类似术语旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。Dyne 可能无法实际实现这些前瞻性声明中披露的计划、意图或期望，您不应对这些前瞻性声明过度依赖。实际结果或事件可能因各种重要因素而与这些前瞻性声明中披露的计划、意图和期望有实质性差异，包括：在识别和开发产品候选者过程中固有的不确定性，包括临床前研究和临床试验的启动和完成；临床前研究和临床试验结果的可用性和时间的不确定性；Dyne 在临床试验中招募患者的时间及能力；临床前研究的结果和早期临床试验的初步数据是否能预测临床试验或未来试验的最终结果；FDA 及其他监管机构对 Dyne 临床试验数据的解释及对 Dyne 临床项目的接受及监管批准过程的不确定性，包括加速批准途径的可用性；Dyne 的现金资源是否足以支持其可预见和不可预见的运营费用和资本支出要求；以及 Dyne 在向证券交易委员会（SEC）提交的文件中识别的风险和不确定性，包括公司最近的 10-Q 表格及 Dyne 可能在 SEC 后续提交的文件。此外，本新闻稿中包含的前瞻性声明代表 Dyne 在本新闻稿日期的观点。Dyne 预计后续事件和发展将导致其观点发生变化。然而，尽管 Dyne 可能选择在未来某个时点更新这些前瞻性声明，但它特别声明没有任何义务这样做。这些前瞻性声明不应被视为代表 Dyne 在本新闻稿日期之后的任何日期的观点。</p>
<p><strong>联系方式：</strong></p>
<p><strong>投资者</strong></p>
<p>Mia Tobias</p>
<p>ir@dyne-tx.com</p>
<p>781-317-0353</p>
<p><strong>媒体</strong></p>
<p>Stacy Nartker</p>
<p>snartker@dyne-tx.com</p>
<p>781-317-1938</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qRTBPQ00zTXpNek5URXdJekl5TURBNE9UST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qRTBPQ00zTXpNek5URXdJekl5TURBNE9UST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDcyYTI2ODMtOGZhNS00NDFjLTlmNWMtMWUwNDJhOWU4OTgwLTEyMTI0NDUtMjAyNS0xMi0yMy1lbg==/tiny/Dyne-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDcyYTI2ODMtOGZhNS00NDFjLTlmNWMtMWUwNDJhOWU4OTgwLTEyMTI0NDUtMjAyNS0xMi0yMy1lbg==/tiny/Dyne-Therapeutics-Inc-.png"/></p>

<p>Dyne Therapeutics 已任命 Vikram Karnani 为其董事会成员。Karnani 是 Collegium Pharmaceutical 的首席执行官，拥有丰富的罕见疾病和生物制药领域的经验。他的任命预计将有助于 Dyne 的商业化努力和增长。Dyne 专注于开发神经肌肉疾病的治疗药物，计划在 2027 年第一季度推出其首款产品。Karnani 在商业运营和医学事务方面的领导能力与 Dyne 改变神经肌肉疾病护理的目标相一致</p>

<p>WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics.</p>
<div class="lb-trans"><p>马萨诸塞州沃尔瑟姆，2025 年 12 月 23 日（GLOBE NEWSWIRE）——Dyne Therapeutics, Inc.（纳斯达克：DYN）是一家专注于为患有基因驱动的神经肌肉疾病的人群提供功能改善的临床阶段公司，今天宣布任命 Vikram Karnani 为其董事会成员。Karnani 先生在罕见疾病和生物制药领域拥有丰富的商业和高管领导经验，目前担任 Collegium Pharmaceutical 的首席执行官，并在 Horizon Therapeutics 担任多个业务线和职能的领导近十年。</p>
</div><p>“We are pleased to welcome Vikram to our Board as we advance toward commercialization,” said Jason Rhodes, chairman of Dyne’s Board of Directors and partner at Atlas Venture. “As a CEO and former commercial leader of a biotechnology company that grew quickly and successfully, Vikram brings valuable experience in launching products, driving growth, and realizing value. His insights will further Dyne’s progress toward generating revenue and expanding our portfolio.”</p>
<div class="lb-trans"><p>“我们很高兴欢迎 Vikram 加入我们的董事会，随着我们向商业化迈进，” Dyne 董事会主席、Atlas Venture 合伙人 Jason Rhodes 表示。“作为一家快速成功发展的生物技术公司的首席执行官和前商业领导者，Vikram 带来了在产品推出、推动增长和实现价值方面的宝贵经验。他的见解将进一步推动 Dyne 在创造收入和扩展我们的产品组合方面的进展。”</p>
</div><p>“Throughout my career, I’ve focused on translating innovation into highly successful businesses that unlock value and improve the lives of patients,” said Vikram Karnani. “Dyne’s clinically validated drug delivery approach and progress towards commercialization underscore its potential to deliver meaningful functional improvement for people living with neuromuscular diseases. I’m excited to join the Board at this pivotal stage as the company works to realize its full potential and build shareholder value.”</p>
<div class="lb-trans"><p>“在我的职业生涯中，我一直专注于将创新转化为高度成功的企业，以释放价值并改善患者的生活，” Vikram Karnani 表示。“Dyne 经过临床验证的药物递送方法和向商业化的进展凸显了其为患有神经肌肉疾病的人群提供有意义的功能改善的潜力。我很高兴在公司努力实现其全部潜力并为股东创造价值的关键阶段加入董事会。”</p>
</div><p>“Vikram’s track record of running world-class commercial and medical organizations will add an important perspective to our Board as we prepare for our first potential launch in Q1 2027,” said John Cox, president and chief executive officer of Dyne. “His experience leading rare disease portfolios, particularly through periods of rapid growth, aligns exceptionally well with our goal of building a commercial company with multiple opportunities to create value and potentially transform care for neuromuscular diseases.”</p>
<div class="lb-trans"><p>“Vikram 在运营世界级商业和医疗组织方面的成功记录将为我们的董事会增添重要视角，因为我们为 2027 年第一季度的首次潜在推出做准备，” Dyne 总裁兼首席执行官 John Cox 表示。“他在领导罕见疾病产品组合方面的经验，特别是在快速增长时期，与我们建立一个拥有多个创造价值机会并可能改变神经肌肉疾病护理的商业公司的目标非常契合。”</p>
</div><p>Mr. Karnani has served as president and chief executive officer of Collegium Pharmaceutical since November 2024. Collegium is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, with a leading portfolio in responsible pain management and a growing neuropsychiatry business. Prior to joining Collegium, he was executive vice president and president, global commercial operations and medical affairs (rare disease) at Amgen where he led the integration and growth of the company’s approximately $4 billion rare disease business following the $28 billion acquisition of Horizon Therapeutics. During nearly a decade at Horizon, Mr. Karnani held multiple senior executive roles, including president of global commercial operations and chief commercial officer, where he helped transform the company from a $500 million in revenue enterprise into a rare disease leader generating more than $3 billion in revenue through disciplined strategy, M&amp;A, capital deployment and commercialization. Earlier in his career, Mr. Karnani served as vice president of the therapeutics and cell therapy business and held leadership roles in strategy and business development at Fresenius Kabi.</p>
<div class="lb-trans"><p>Karnani 先生自 2024 年 11 月以来担任 Collegium Pharmaceutical 的总裁兼首席执行官。Collegium 是一家多元化的生物制药公司，致力于改善患有严重医疗状况的人的生活，拥有在负责任的疼痛管理领域的领先产品组合以及不断增长的神经精神病学业务。在加入 Collegium 之前，他曾担任安进（Amgen）的执行副总裁和全球商业运营及医疗事务（罕见疾病）总裁，领导公司在以 280 亿美元收购 Horizon Therapeutics 后，整合和发展约 40 亿美元的罕见疾病业务。在 Horizon 的近十年间，Karnani 先生担任多个高级执行职务，包括全球商业运营总裁和首席商业官，帮助公司通过严谨的战略、并购、资本部署和商业化，将其从一家年收入 5 亿美元的企业转变为年收入超过 30 亿美元的罕见疾病领导者。在职业生涯早期，Karnani 先生曾担任治疗和细胞治疗业务的副总裁，并在 Fresenius Kabi 担任战略和业务发展方面的领导职务。</p>
</div><p>Mr. Karnani holds a bachelor’s degree in electrical engineering from the University of Mumbai, a master’s degree in electrical engineering from Case Western Reserve University and an MBA from Northwestern University’s Kellogg School of Management.</p>
<div class="lb-trans"><p>Karnani 先生拥有孟买大学的电气工程学士学位、凯斯西储大学的电气工程硕士学位以及西北大学凯洛格管理学院的 MBA 学位。</p>
</div><p><strong>About Dyne Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Dyne Therapeutics</strong></p>
</div><p>Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.</p>
<div class="lb-trans"><p>Dyne Therapeutics 专注于为患有基因驱动的神经肌肉疾病的人群提供功能改善。我们正在开发针对肌肉和中枢神经系统（CNS）的治疗方法，以解决疾病的根本原因。公司正在推进针对肌强直性肌营养不良症 1 型（DM1）和杜氏肌营养不良症（DMD）的临床项目，以及针对面肩肱肌营养不良症（FSHD）和庞贝病的前临床项目。在 Dyne，我们的使命是为个人、家庭和社区提供功能改善。了解更多信息 https://www.dyne-tx.com/，并在 X、LinkedIn 和 Facebook 上关注我们。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCETM platform, expectations regarding the timing and outcome of interactions with and submissions to global regulatory authorities and anticipated timelines for submission for regulatory approval and launch of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne’s ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and the regulatory approval process, including the availability of accelerated approval pathways; whether Dyne’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.</p>
<div class="lb-trans"><p>本新闻稿包含涉及重大风险和不确定性的前瞻性声明。除历史事实陈述外，本新闻稿中包含的所有陈述，包括关于 Dyne 的战略、未来运营、前景和计划、管理目标、FORCETM 平台的潜力、与全球监管机构的互动和提交的时间及结果的预期，以及 zeleciment rostudirsen（z-rostudirsen，也称为 DYNE-251）监管批准和上市的预期时间表，均构成 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。术语 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“可能”、“目标”、“正在进行”、“计划”、“预测”、“项目”、“潜力”、“应该”、“将” 或 “会”，或这些术语的否定形式，或其他类似术语旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。Dyne 可能无法实际实现这些前瞻性声明中披露的计划、意图或期望，您不应对这些前瞻性声明过度依赖。实际结果或事件可能因各种重要因素而与这些前瞻性声明中披露的计划、意图和期望有实质性差异，包括：在识别和开发产品候选者过程中固有的不确定性，包括临床前研究和临床试验的启动和完成；临床前研究和临床试验结果的可用性和时间的不确定性；Dyne 在临床试验中招募患者的时间及能力；临床前研究的结果和早期临床试验的初步数据是否能预测临床试验或未来试验的最终结果；FDA 及其他监管机构对 Dyne 临床试验数据的解释及对 Dyne 临床项目的接受及监管批准过程的不确定性，包括加速批准途径的可用性；Dyne 的现金资源是否足以支持其可预见和不可预见的运营费用和资本支出要求；以及 Dyne 在向证券交易委员会（SEC）提交的文件中识别的风险和不确定性，包括公司最近的 10-Q 表格及 Dyne 可能在 SEC 后续提交的文件。此外，本新闻稿中包含的前瞻性声明代表 Dyne 在本新闻稿日期的观点。Dyne 预计后续事件和发展将导致其观点发生变化。然而，尽管 Dyne 可能选择在未来某个时点更新这些前瞻性声明，但它特别声明没有任何义务这样做。这些前瞻性声明不应被视为代表 Dyne 在本新闻稿日期之后的任何日期的观点。</p>
</div><p><strong>Contacts:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投资者</strong></p>
</div><p>Mia Tobias</p>
<div class="lb-trans"><p>Mia Tobias</p>
</div><p>ir@dyne-tx.com</p>
<div class="lb-trans"><p>ir@dyne-tx.com</p>
</div><p>781-317-0353</p>
<div class="lb-trans"><p>781-317-0353</p>
</div><p><strong>Media</strong></p>
<div class="lb-trans"><p><strong>媒体</strong></p>
</div><p>Stacy Nartker</p>
<div class="lb-trans"><p>Stacy Nartker</p>
</div><p>snartker@dyne-tx.com</p>
<div class="lb-trans"><p>snartker@dyne-tx.com</p>
</div><p>781-317-1938</p>
<div class="lb-trans"><p>781-317-1938</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qRTBPQ00zTXpNek5URXdJekl5TURBNE9UST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjE0OCM3MzMzNTEwIzIyMDA4OTI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDcyYTI2ODMtOGZhNS00NDFjLTlmNWMtMWUwNDJhOWU4OTgwLTEyMTI0NDUtMjAyNS0xMi0yMy1lbg==/tiny/Dyne-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MDcyYTI2ODMtOGZhNS00NDFjLTlmNWMtMWUwNDJhOWU4OTgwLTEyMTI0NDUtMjAyNS0xMi0yMy1lbg==/tiny/Dyne-Therapeutics-Inc-.png"/></p>

Dyne Therapeutics 任命 Vikram Karnani 加入董事会 | DYN 股票新闻